OTC:PAXH
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
A pre-revenue biotech firm with minimal assets funded by equity raises to develop new therapeutic candidates.
Key Metrics
Investment Thesis
Bull Case
An investor might consider this stock if they believe the company can successfully raise additional capital through equity or debt financing before running out of cash, thereby extending its runway to bring a promising drug candidate to market and potentially generate significant returns upon successful commercialization.
Bear Case
The investment case is extremely weak given the company's negative shareholders' equity, zero revenue history, and massive operating losses that have depleted cash reserves, creating a high probability of bankruptcy or forced liquidation before any product can reach the market.
About PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
Preaxia Healthcare Payment Systems Inc. is a micro-cap biotechnology company focused on developing novel therapeutic candidates to address unmet needs in oncology and other disease areas. The company currently operates without significant revenue streams, relying entirely on financing activities to fund its research and development pipeline. Its financial profile reflects a classic pre-commercial stage where all cash flow from operations is negative as it invests heavily into potential future products.
Analysis
Management Discussion
Recent financial performance indicates a deepening operational challenge with a net loss of approximately $0.1 million in 2024 following losses exceeding $0.2 million in 2023, driven by operating expenses that consumed the entire cash balance while contributing to a total liabilities and equity position that barely covers current assets. The company's cash flow from operations remains deeply negative at roughly $30.9 million on an annualized basis relative to its tiny cash reserve, suggesting it is burning through its limited resources rapidly without any income generation.
Industry Overview
The biotechnology industry is characterized by high capital intensity and significant regulatory hurdles, where companies often operate at substantial losses for many years while developing products before achieving commercial viability. While this sector offers the potential for outsized returns on successful breakthroughs, it also carries extreme risks of total capital loss for firms that fail to secure funding or advance their pipelines.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $0 | $0 |
| Operating Expenses | $156.3K | $99.4K |
| Operating Income | $-156.3K | $-99.4K |
| R&D | $6.5K | $5.6K |
| G&A | $13.8K | $15.2K |
| Other OpEx | $135.9K | $78.7K |
| Non-Operating Income | $0 | $0 |
| Pre-Tax Income | $-156.3K | $-99.4K |
| Income Tax | $0 | $0 |
| Continuing Ops | $-156.3K | $-99.4K |
| Discontinued Ops | $0 | $0 |
| Net Income | $-156.3K | $-99.4K |
| Minority Interest | $0 | $0 |
| Net to Common | $-156.3K | $-99.4K |
| Metric | 2023 | 2024 |
|---|---|---|
| Current Assets | $6 | $14 |
| Cash & Equivalents | $6 | $14 |
| Other Current Assets | $0 | $0 |
| Long-Term Assets | $0 | $0 |
| Total Assets | $6 | $14 |
| Current Liabilities | $2.3M | $2.4M |
| Long-Term Liabilities | $0 | $0 |
| Total Liabilities | $2.3M | $2.4M |
| Shareholders' Equity | $-2.3M | $-2.4M |
| Paid-In Capital | $2.7M | $2.7M |
| Retained Earnings | $-5.0M | $-5.1M |
| AOCI | $57.2K | $57.2K |
| Total L&E | $6 | $14 |
| Metric | 2023 | 2024 |
|---|---|---|
| Net Income (CFO) | $-156.3K | $-99.4K |
| Non-Cash Adjustments | $0 | $0 |
| Working Capital Changes | $118.6K | $68.6K |
| Cash from Operations | $-37.6K | $-30.9K |
| Cash from Investing | $0 | $0 |
| Cash from Financing | $37.4K | $30.9K |
| FX Effect | $0 | $14 |
| Net Change in Cash | $-253 | $8 |
| Beginning Cash | $259 | $6 |
| Ending Cash | $6 | $14 |
Frequently Asked Questions
How does PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. make money?
The company's operations are currently consolidated under a single development segment focused on early-stage drug discovery and clinical trials, as evidenced by zero reported revenue and all costs classified under research and development and general administrative expenses.
What are the main risks for PAXH?
The company faces severe liquidity risks with total liabilities exceeding shareholders' equity by over $2.4 million, a substantial risk of dilution from repeated equity financing to sustain operations, an inability to generate positive cash flow from operations leading to a significant retained earnings deficit, and the high probability of failure inherent in early-stage drug development without proven product candidates.
What is PAXH's competitive advantage?
Despite current financial constraints, the company possesses the potential to create value through proprietary intellectual property in high-demand therapeutic areas like oncology if its pipeline candidates successfully advance through regulatory approval and commercialization.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.